SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 190.43-0.7%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (8033)9/29/1997 6:27:00 PM
From: Henry Niman   of 32384
 
Here's the Dow Jones version (not sure when it came out):

Ligand Finds Phase II/III Data For Targretin 'Favorable'

SAN DIEGO (Dow Jones)--Ligand Pharmaceuticals Inc. (LGND) said phase
II/III data for its Targretin capsules to treat cutaneous T-cell lymphoma, or
CTCL, are "favorable."

In a press release Monday, Ligand Pharmaceuticals said patients who had
been refractory or intolerant to prior therapy "achieved a complete or partial
response" from dosages of Targretin capsules.

The company said that of 21 patients with advanced stage CTCL, who
received a higher dose of Targretin capsules, 43% showed complete or partial
response and 33% achieved stabilization of disease.

Ligand said that of 15 patients with early stage CTCL, who received a lower
dose of Targretin, 37% showed partial or complete response.

Ligand Pharmaceuticals anticipates filing new drug applications for Targretin
Capsules and Topical Gel in the second half of 1998.

The company said Targretin is a synthetic retinoid analogue which selectively
activates a subclass of retinoid receptors called retinoid X receptors that play
"an important role" in several cellular activities, including programmed cell
death, a natural process by which the body rids itself of unwanted cells.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News